Rachel Midgley

4.9k total citations · 1 hit paper
56 papers, 2.8k citations indexed

About

Rachel Midgley is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Rachel Midgley has authored 56 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 24 papers in Pathology and Forensic Medicine and 12 papers in Molecular Biology. Recurrent topics in Rachel Midgley's work include Colorectal Cancer Treatments and Studies (27 papers), Genetic factors in colorectal cancer (21 papers) and Colorectal Cancer Surgical Treatments (11 papers). Rachel Midgley is often cited by papers focused on Colorectal Cancer Treatments and Studies (27 papers), Genetic factors in colorectal cancer (21 papers) and Colorectal Cancer Surgical Treatments (11 papers). Rachel Midgley collaborates with scholars based in United Kingdom, United States and Qatar. Rachel Midgley's co-authors include Rachel Kerr, Elaine Johnstone, Ian Tomlinson, Axel Walther, Charles Swanton, David Kerr, Enric Domingo, Christopher C. McConkey, David N. Church and Yoko Yanagisawa and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Rachel Midgley

56 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic prognostic and predictive markers in colorectal cancer

2009 529 citations Elaine Johnstone, Rachel Midgley et al. profile →

Peers

Countries citing papers authored by Rachel Midgley

Since Specialization

Citations

This map shows the geographic impact of Rachel Midgley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Midgley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Midgley more than expected).

Fields of papers citing papers by Rachel Midgley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Midgley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Midgley. The network helps show where Rachel Midgley may publish in the future.

Co-authorship network of co-authors of Rachel Midgley

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Midgley. A scholar is included among the top collaborators of Rachel Midgley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Midgley. Rachel Midgley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer 2013 ·European Journal of Cancer ·David N. Church, Enric Domingo, Oliver M. Sieber, Rajarajan Ramamoorthy, BR Davidson, DJ Kerr, Rachel Midgley, (unknown)	7
2	An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer 2013 ·Investigational New Drugs ·Joanne E. Brady, Pippa Corrie, Ian Chau, Raghunadharao Digumarti, Laurel M. Adams, Jeffrey Botbyl, Kevin Laubscher, Rachel Midgley, Mohandas K. Mallath	9
3	TGF-β: An emerging player in drug resistance 2013 ·Cell Cycle ·Diede Brunen, Stefan M. Willems, Udo Kellner, Rachel Midgley, Iris Simón, René Bernards	108
4	The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial 2012 ·Annals of Oncology ·A. Huijbers, Rob A.�E.�M. Tollenaar, Gabi W. van Pelt, Eliane C.M. Zeestraten, Susan Dutton, Christopher C. McConkey, Enric Domingo, Vincent T.H.B.M. Smit, Rachel Midgley, B F Warren, Elaine Johnstone, David Kerr, Wilma E. Mesker	252
5	Biomarkers in Early-Stage Colorectal Cancer: Ready for Prime Time? 2012 ·Digestive Diseases ·David N. Church, Rachel Midgley, David Kerr	28
6	Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors 2012 ·Investigational New Drugs ·Gary K. Schwartz, Richard D. Carvajal, Rachel Midgley, Scott J. Rodig, Paul K. Stockman, Ö. Ataman, David M. Wilson, Shampa Das, Geoffrey I. Shapiro	61
7	The emergence of ‘omics for the management of colorectal cancer 2011 ·Current Opinion in Oncology ·Rachel Midgley, David N. Church, Rachel Kerr	3
8	TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres 2011 ·Gut ·Angela M. Jones, Andrew D. Beggs, Luis G. Carvajal‐Carmona, Susan M. Farrington, Albert Tenesa, Marion Walker, Kimberley Howarth, Stéphane Ballereau, S V Hodgson, Ann G. Zauber, Monica M. Bertagnolli, Rachel Midgley, Harry Campbell, Rachel Kerr, Malcolm G. Dunlop, Ian Tomlinson	75
9	Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients 2010 ·Journal of Human Genetics ·Carolina Bonilla, Jérémie H. Lefèvre, Bruce Winney, Elaine Johnstone, Susan Tonks, Chrystelle Colas, Tammy Day, Katarzyna Hutnik, Abdelhamid Boumertit, Rachel Midgley, Rachel Kerr, Yann Parc, Walter F. Bodmer	9
10	Regional Hepatic Chemotherapies in the Treatment of Colorectal Cancer Metastases to the Liver 2010 ·Seminars in Oncology ·(unknown), Rachel Midgley, Rachel Kerr	16
11	A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer 2009 ·Cancer Chemotherapy and Pharmacology ·Ami Sabharwal, Pippa Corrie, Rachel Midgley, (unknown), Joanne E. Brady, Peter G. Mortimer, Amanda J. Watson, Geoffrey P. Margison, Mark R. Middleton	13
12	A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma† 2008 ·Hepatology ·Daniel H. Palmer, Rachel Midgley, Noweeda Mirza, Elizabeth Torr, Forhad Ahmed, Jane C. Steele, Neil Steven, Rachel Kerr, Lawrence S. Young, David Adams	235
13	A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer 2008 ·British Journal of Cancer ·Omar Khan, (unknown), Michalis Michael, Ian Olver, N C Levitt, Peter G. Mortimer, (unknown), (unknown), Rachel Midgley, Mark R. Middleton	45
14	A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan 2007 ·Annals of Oncology ·Rachel Midgley, Rachel Kerr, Keith T. Flaherty, James Stevenson, Sarah Pratap, Kevin M. Koch, Deborah A. Smith, M. Versola, Ronald A. Fleming, Cynthia R. Ward, Peter J. O’Dwyer, Mark R. Middleton	43
15	Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer 2007 ·New England Journal of Medicine ·David J. Kerr, Janet Dunn, M. J. S. Langman, (unknown), Rachel Midgley, Andrew Stanley, (unknown), Patrick Julier, (unknown), (unknown), Christopher C. McConkey	95
16	Bevacizumab—current status and future directions 2005 ·Annals of Oncology ·Rachel Midgley, Rachel Kerr	75
17	Adjuvant chemotherapy for stage II colorectal cancer: the time is right! 2005 ·Nature Clinical Practice Oncology ·Rachel Midgley, Rachel Kerr	27
18	ABC of colorectal cancer: Adjuvant therapy 2000 ·BMJ ·Rachel Midgley	25
19	Immunotherapy for colorectal cancer:a challenge to clinical trial design 2000 ·The Lancet Oncology ·Rachel Midgley, Rachel Kerr	11
20	Adjuvant Therapy of Colorectal Cancer 2000 ·Hospital Practice ·Rachel Midgley, David Kerr	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact